The increasing prevalence of obesity worldwide is expected to fuel the growth of the orlistat market. For instance, around 38 million children aged 5 years or less were overweight or obese in 2019, according to the World Health Organization (WHO). Obesity is defined as having a body mass index equal to or greater than 30.
Moreover, increasing demand for orlistat, as well as speedy approvals by regulatory authorities for biosimilars, especially in North America, are expected to propel the growth of the orlistat market. For instance, in December 2020, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval for Saxenda (liraglutide) injection for the treatment of obesity in adolescents (aged 12 to 17 years) with a bodyweight above 60 kg.
The launch of the new generic version of orlistat and the increasing number of awareness campaigns for weight management are also expected to drive the orlistat market growth.
Competitive Analysis
Major players operating in the orlistat market are Kabir Life Sciences and Research Pvt. Ltd., China Zhongshan Pharma, D.M. Pharma, Taj Pharmaceuticals Ltd., HISUN Pharmaceuticals Co. Ltd., ZEIN Pharmaceutical Co. Ltd., Lunan Pharmaceutical Group Corporation Ltd., National Company for Pharmaceutical Industry, Hexal AG., STADA–VN J.V. Co., Sandoz Pharmaceuticals, Teva Pharmaceutical Industries, GlaxoSmithKline, and Roche Holding AG.
Major players in the market are adopting various strategies such as collaborations, partnerships, product launches, etc. to enhance their market position. For instance, in 2018, H2-Pharma and CHEPLAPHARM re-launched XENICAL (orlistat) 120 mg Capsules in the U.S. market... Read more